Tirzepatide activates two receptors and produces 22.5% weight loss
This catches early absorption changes After each significant weight milestone (every 10-15 pounds lost): Recheck TSH and free T4 Every 3-4 months during active weight loss phase: Full thyroid panel including TSH, free T4, free T3 After weight stabilization: Return to every 6 months for the first year, then annually if stable This is more frequent than most GLP-1 prescribers recommend for non-thyroid patients
At these lower initial doses, the appetite-suppressing and metabolic effects of semaglutide are present but not yet at their maximum potential
Given Medicares predicament across the pond, theyre unlikely to oblige
Using them can lead to failed tests and suspensions
According to the MHRA's latest guidance, while occurrences are rare, there have been reports of severe, necrotizing, and even fatal pancreatitis associated with GLP-1 and GIP receptor agonists